Answers are grounded in this paper and cite their sources.
The voltage-gated sodium channel isoform Na V 1.7 is highly expressed in small diameter dorsal root ganglion neurons and is obligatory for nociceptive signal transmission. Genetic gain-of-function and loss-of-function Na V 1.7 mutations have been identified in select individuals, and are associated with episodic extreme pain disorders and insensitivity to pain, respectively. These findings implicate Na V 1.7 as a key pharmacotherapeutic target for the treatment of pain. While several small molecules targeting Na V 1.7 have been advanced to clinical development, no Na V 1.7-selective compound has shown convincing efficacy in clinical pain applications. Here we describe the discovery and characterization of ST-2262, a Na V 1.7 inhibitor that blocks the extracellular vestibule of the channel with an IC 50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, Na V 1.1–1.6 and Na V 1.8. In contrast to other Na V 1.7 inhibitors that preferentially inhibit the inactivated state of the channel, ST-2262 is equipotent against resting and inactivated protein conformers. In a non-human primate model, animals treated with ST-2262 exhibit markedly reduced sensitivity to noxious heat. These findings establish the extracellular vestibule of the sodium channel as a viable receptor site for selective ligand design and provide insight into the pharmacology of state-independent inhibition of Na V 1.7. Significance Statement Pain is among the most common reasons for seeking medical care, yet many frequently prescribed drugs, particularly the opioids, cause problematic side effects and carry a risk of addiction. Voltage-gated sodium ion channels (Na V s) have emerged as promising targets for the development of non-opioid pain medicines. Na V s are involved in the propagation of electrical signals along neurons throughout the body. Humans born without a functional copy of one sodium channel subtype, Na V 1.7, are unable to experience most types of pain. In the present work, we disclose the discovery and characterization of a selective inhibitor of Na V 1.7 that reduces sensitivity to a painful thermal stimulus in non-human primates. Findings from this work may help guide the development of novel, non-addictive drug candidates as alternatives to opioids.
No takes yet. Share an insight, caveat, or question.
Pajouhesh et al. (2019) studied this question.